PartnershipJul 21, 2026, 07:31 AM
Plus Therapeutics Subsidiary Signs Medical Mutual Agreement, Expands Coverage
AI Summary
Plus Therapeutics' wholly-owned subsidiary, CNSide Diagnostics, LLC, announced a regional agreement with Medical Mutual, effective July 1, 2026. This partnership expands coverage for the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay to approximately 1.2 million people in Ohio and Kentucky, bringing the total contracted coverage to about 127 million people. The CNSide® assay has been used in over 11,000 tests since 2020, showing high sensitivity and specificity. Additionally, Plus Therapeutics will change its corporate name to Cerenome, Inc. and its Nasdaq ticker symbol to CNSY, effective August 3, 2026.
Key Highlights
- CNSide Diagnostics signed a regional agreement with Medical Mutual effective July 1, 2026.
- The agreement covers approximately 1.2 million people throughout Ohio and Kentucky.
- Total contracted coverage for the CNSide® CSF TCE assay now reaches approximately 127 million people.
- Over 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions since 2020.
- The CNSide® test demonstrates 92% sensitivity and 95% specificity.
- The test influences treatment decisions in 90% of cases.
- Plus Therapeutics will change its corporate name to Cerenome, Inc. and ticker to CNSY effective August 3, 2026.
Price Impact
More from PSTV